Share

The discovery of a "fusion toxin that specifically targets cancer cells," could provide a treatment option for patients who become resistant to chemotherapy, according to a hospital news release.

"Although we have made tremendous progress in the treatment of leukemia, Dr. Heisterkamp and her colleagues’ research into drug-resistant disease fills a crucial need," said Brent Polk, MD, director of The Saban Research Institute.

ALL, the most commonly diagnosed cancer in children, also accounts for 30% of adult leukemia.